More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$281670040
EPS
-0.53
P/E ratio
--
Price to sales
9.48
Dividend yield
--
Beta
2.085838
Previous close
$1.87
Today's open
$1.90
Day's range
$1.82 - $1.94
52 week range
$1.66 - $3.94
show more
CEO
Gilmore ONeill
Employees
87
Headquarters
Cambridge, MA
Exchange
Nasdaq Global Select
Shares outstanding
154339748
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Editas Medicine Plans Human Trial After Gene Therapy Slashed LDL 90% in Primate Study
Editas Medicine NASDAQ: EDIT expects to dose the first patients this year in a Phase I/II study of its lead gene-editing candidate, EDIT-401, as the company focuses its development strategy on in vivo CRISPR therapies.
MarketBeat • Nov 10, 2026

Editas Medicine Announces Third Quarter 2026 Results and Business Updates
Company received HREC approval to initiate Phase 1/2 Strive™ study of EDIT-401 in patients with hyperlipidemia in Australia New preclinical data presented at AHA Scientific Sessions demonstrating ≥90 percent LDL-C reduction maintained over 10 months supports EDIT-401's potential best-in-class profile Second IND/CTA accepted for CD70 HD Allo CAR T program as part of collaboration with Bristol Myers Squibb, triggering milestone payment to Editas Cash runway into second half of 2028, through and beyond key clinical readouts from Strive study CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the third quarter 2026 and provided business updates.
GlobeNewsWire • Nov 9, 2026

Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates
Editas Medicine (EDIT) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.28 per share a year ago.
Zacks Investment Research • Nov 9, 2026

Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference
CAMBRIDGE, Mass., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced two poster presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress, to be held October 27-30, 2026, in Hamburg, Germany.
GlobeNewsWire • Oct 14, 2026

EDIT Set to Begin First-in-Human Study in Hypercholesterolemia
Editas Medicine gains approval to launch the first-in-human phase I/II study of EDIT-401 in Australia, targeting LDL cholesterol through gene editing.
Zacks Investment Research • Oct 9, 2026

Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia
Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering Company remains on track to begin patient dosing this year and report initial safety and tolerability data in the first quarter of 2027 New EDIT-401 preclinical data demonstrating durability of LDL-C reduction to be presented in oral presentation at AHA Scientific Sessions 2026 CAMBRIDGE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced it has received approval to initiate the Phase 1/2 Strive™ clinical trial of EDIT-401 in patients with Heterozygous Familial Hypercholesterolemia (HeFH) in Australia.
GlobeNewsWire • Oct 8, 2026

Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy
Editas Medicine NASDAQ: EDIT outlined its strategy as an in vivo gene-editing company and said it remains on track to dose patients this year in a clinical study of its lead program, EDIT-401, for lowering LDL cholesterol.
MarketBeat • Sep 12, 2026

Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401
Editas Medicine NASDAQ: EDIT is preparing to begin a first-in-human study of EDIT-401, an in vivo CRISPR-edited medicine designed to lower LDL cholesterol in patients with heterozygous familial hypercholesterolemia, Chief Executive Officer Gilmore O'Neill said during a Wells Fargo discussion.
MarketBeat • Sep 9, 2026

Editas Medicine Reports Inducement Grants to New Chief Medical Officer
CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the grant of an inducement award to the Company's newly appointed Chief Medical Officer, Daniel Ory, M.D.
GlobeNewsWire • Sep 9, 2026

Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer
Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development
GlobeNewsWire • Sep 8, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Editas Medicine Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.